Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) hit a new 52-week low on Tuesday. The company traded as low as C$13.37 and last traded at C$13.27, with a volume of 10,398 shares changing hands. The stock had previously closed at C$13.40.
Cipher Pharmaceuticals Trading Down 0.8%
The company has a debt-to-equity ratio of 0.44, a current ratio of 1.99 and a quick ratio of 2.67. The company has a market cap of C$337.77 million, a price-to-earnings ratio of 11.87 and a beta of 1.29. The business’s 50-day simple moving average is C$13.74 and its 200-day simple moving average is C$15.72.
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last released its earnings results on Thursday, November 12th. The company reported C$0.60 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a net margin of 69.98% and a return on equity of 25.48%. The company had revenue of C$18.08 million for the quarter. Research analysts predict that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current fiscal year.
Insider Activity at Cipher Pharmaceuticals
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
See Also
- Five stocks we like better than Cipher Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
